BI 836847

BI 836847 is an Fc-engineered isotype control monoclonal antibody developed by Boehringer Ingelheim. It is primarily utilized in preclinical and clinical research as a negative control for other Fc-optimized therapeutic antibodies, such as the anti-CD33 antibody BI 836858. BI 836847 is designed to possess the same Fc-region modifications—typically engineered to enhance affinity for Fcγ receptors like CD16 (FcγRIIIa) to boost antibody-dependent cellular cytotoxicity (ADCC)—while lacking a specific binding variable region for the target antigens under study (e.g., CD33 in acute myeloid leukemia). This allows researchers to distinguish between target-specific therapeutic activity and non-specific immune activation or effector functions mediated by the engineered Fc portion.

Other names

Fc-engineered isotype control antibody